INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz (retifanlimab) for a second indication. The drug is now approved in the EU in combination with chemotherapy for the first-line treatment of adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Zynyz is a PD-1 immune checkpoint inhibitor designed to help the immune system recognize and attack cancer cells. The decision marks the first systemic treatment approved in Europe for newly diagnosed patients with advanced SCAC and expands Incyte's growing oncology portfolio. Shares of Incyte have gained 34.4% in the past year compared with the industry's 12.5% growth. Zacks Investment Research Image Source: Zacks Investment Research More on INCY's Zynyz The EC approval was based on results from the late-stage POD1UM-303 (InterAACT2) study, which evaluated Zynyz or placebo in combination with platinum-based chemoth
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.MarketBeat
- Incyte Announces Executive Leadership AppointmentsBusiness Wire
- Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.MarketBeat
- Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
- Incyte: An Undervalued Healthcare Gem [Seeking Alpha]Seeking Alpha
INCY
Earnings
- 2/10/26 - Beat
INCY
Sec Filings
- 3/26/26 - Form 8-K
- 3/19/26 - Form 4
- 3/17/26 - Form 144
- INCY's page on the SEC website